Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia - PubMed (original) (raw)
Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia
Masaru Nagato et al. Crit Care Med. 2009 Jul.
Abstract
Objective: In addition to the hyperactivation of the inflammatory cytokines, high-mobility group box-1 protein (HMGB1), recently identified as a lethal late-phase mediator is suspected to be closely correlated with the development of sepsis. Therefore, the therapeutic efficacy of recombinant human soluble thrombomodulin (ART-123) administration on the production of inflammatory cytokines and the plasma level of HMGB1 was investigated in experimental endotoxemia.
Design: Prospective, comparative, experimental study.
Setting: Laboratory animal research center at a university.
Subjects: Male Sprague-Dawley rats (250-300 g).
Interventions: Endotoxemia was induced in rats by a bolus intravenous injection of lipopolysaccharide (LPS) at a dosage of 4 mg/kg (LPS group). ART-123 (1 mg/kg) was administered as a bolus injection 30 minutes before or 4 hours after injection of LPS (ART-123 pretreated/treated group). As a control, an equal volume of physiologic saline was administered instead of LPS and ART-123 (control group).
Measurements and main results: Rats were randomly divided into ART-123 pretreated group, ART-123 treated group, and LPS group, respectively. After the injection of LPS, the levels of inflammatory cytokines and thrombin-antithrombin III complex, plasma HMGB1 concentrations, liver immunohistochemical and histopathologic characteristics, liver dysfunction, and survival rate were examined. The increased levels of inflammatory cytokines and plasma HMGB1 induced by LPS in this rat model were improved by the administration of ART-123; additionally, reduced liver dysfunction and increased survival rate were observed.
Conclusions: This study demonstrated that ART-123 inhibits the expression of inflammatory cytokines and decreases the plasma HMGB1 levels in experimental endotoxemia. In addition, ART-123 administration markedly reduced liver dysfunction and mortality even with delayed treatment of ART-123. The use of ART-123 may therefore be a beneficial treatment for septic patients.
Similar articles
- Thrombomodulin improved liver injury, coagulopathy, and mortality in an experimental heatstroke model in mice.
Kawasaki T, Okamoto K, Kawasaki C, Sata T. Kawasaki T, et al. Anesth Analg. 2014 May;118(5):956-63. doi: 10.1213/ANE.0000000000000170. Anesth Analg. 2014. PMID: 24781566 - In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models.
Hagiwara S, Iwasaka H, Matsumoto S, Hasegawa A, Yasuda N, Noguchi T. Hagiwara S, et al. Shock. 2010 Mar;33(3):282-8. doi: 10.1097/SHK.0b013e3181b0ef7b. Shock. 2010. PMID: 19536047 - Recombinant human soluble thrombomodulin improved lipopolysaccharide/d-galactosamine-induced acute liver failure in mice.
Osumi W, Jin D, Imai Y, Tashiro K, Li ZL, Otsuki Y, Maemura K, Komeda K, Hirokawa F, Hayashi M, Takai S, Uchiyama K. Osumi W, et al. J Pharmacol Sci. 2015 Dec;129(4):233-9. doi: 10.1016/j.jphs.2015.11.007. Epub 2015 Nov 26. J Pharmacol Sci. 2015. PMID: 26712705 - Extracellular role of HMGB1 in inflammation and sepsis.
Wang H, Yang H, Tracey KJ. Wang H, et al. J Intern Med. 2004 Mar;255(3):320-31. doi: 10.1111/j.1365-2796.2003.01302.x. J Intern Med. 2004. PMID: 14871456 Review. - HMGB1 as a potential therapeutic target.
Wang H, Li W, Goldstein R, Tracey KJ, Sama AE. Wang H, et al. Novartis Found Symp. 2007;280:73-85; discussion 85-91, 160-4. Novartis Found Symp. 2007. PMID: 17380789 Review.
Cited by
- Thrombomodulin Improves Cognitive Deficits in Heat-Stressed Mice.
Lin CH, Tang LY, Wang LY, Chang CP. Lin CH, et al. Int J Neuropsychopharmacol. 2024 Jul 1;27(7):pyae027. doi: 10.1093/ijnp/pyae027. Int J Neuropsychopharmacol. 2024. PMID: 38938182 Free PMC article. - Senolysis through thrombomodulation.
Webster CM, van Deursen JM. Webster CM, et al. Cell Res. 2023 Aug;33(8):575-576. doi: 10.1038/s41422-023-00842-y. Cell Res. 2023. PMID: 37402898 Free PMC article. No abstract available. - Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS.
Amini S, Rezabakhsh A, Hashemi J, Saghafi F, Azizi H, Sureda A, Habtemariam S, Khayat Kashani HR, Hesari Z, Sahebnasagh A. Amini S, et al. J Intensive Care. 2022 Jul 30;10(1):38. doi: 10.1186/s40560-022-00625-4. J Intensive Care. 2022. PMID: 35908022 Free PMC article. Review. - Signaling pathways and intervention therapies in sepsis.
Zhang YY, Ning BT. Zhang YY, et al. Signal Transduct Target Ther. 2021 Nov 25;6(1):407. doi: 10.1038/s41392-021-00816-9. Signal Transduct Target Ther. 2021. PMID: 34824200 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials